Linked Life Data

17401086

Source:http://linkedlifedata.com/resource/pubmed/id/17401086

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2007-4-2
pubmed:abstractText
The aim of this study was to evaluate the diagnostic value of a new somatostatin analog, (68)Ga-labeled 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-d-Phe(1)-Tyr(3)-octreotide ((68)Ga-DOTA-TOC), for PET in patients with known or suspected neuroendocrine tumors. PET was compared with conventional scintigraphy and dedicated CT.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0161-5505
pubmed:author
pubmed:issnType
Print
pubmed:volume
48
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
508-18
pubmed:dateRevised
2008-7-22
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.
pubmed:affiliation
Department of Nuclear Medicine, Innsbruck Medical University, Innsbruck, Austria. michael.gabriel@i-med.ac.at
pubmed:publicationType
Journal Article, Clinical Trial, Phase II